Skip to main content
Chase Science Co.,Ltd logo

Chase Science Co.,Ltd — Investor Relations & Filings

Ticker · 300941 ISIN · CNE100004CZ0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2021-01-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300941

About Chase Science Co.,Ltd

https://www.echase.cn

Chase Science Co., Ltd. specializes in the research, development, manufacturing, and distribution of medical puncture instruments and laboratory consumables. The company's core product portfolio includes a wide range of medical devices such as safety syringes, insulin syringes, hypodermic needles, and infusion sets designed for clinical use. Additionally, the firm produces specialized veterinary medical instruments and laboratory plasticware. Chase Science emphasizes the integration of safety-engineered technologies into its products to minimize needle-stick injuries and enhance patient care. With a focus on high-precision manufacturing and international quality standards, the company serves a global market, providing essential medical supplies to healthcare facilities and research institutions. Its operations are characterized by a commitment to technological innovation in the field of medical consumables and puncture technology.

Recent filings

Filing Released Lang Actions
北京市康达律师事务所关于公司首次公开发行股票并在创业板上市的补充法律意见书（一）
Regulatory Filings Classification · 95% confidence The document is a "Supplementary Legal Opinion" issued by a law firm regarding a company's initial public offering (IPO) and listing on the Growth Enterprise Market (创业板) in China. It contains detailed legal opinions, responses to regulatory inquiry letters (问询函), and extensive disclosures about the company's business relationships, contracts, and compliance with securities laws. The document references specific regulatory review processes, legal frameworks, and detailed factual verifications related to the IPO process. It is not a financial report, earnings release, or management discussion, but a legal opinion document supporting the IPO filing. Such legal opinion letters are typically part of the regulatory filings submitted to securities regulators and stock exchanges as part of the IPO application process. Therefore, this document fits best under the category of Regulatory Filings (RNS), which includes compliance documents, legal opinions, and miscellaneous filings that do not fit other specific categories.
2021-01-20 Chinese
兴业证券股份有限公司关于公司首次公开发行股票并在创业板上市之上市保荐书
Regulatory Filings Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document for IPO Listing". It is issued by 兴业证券股份有限公司 (Industrial Securities Co., Ltd.) regarding 福建创识科技股份有限公司's initial public offering (IPO) and listing on the Growth Enterprise Market (创业板). The document contains detailed information about the issuer, business operations, core technologies, financial data, risk factors, issuance details, underwriting, and regulatory compliance. It is a comprehensive document related to the IPO process and listing sponsorship, not a typical financial report like an annual or interim report. It is not a simple announcement or certification but a detailed regulatory filing required for the IPO process. This type of document is best classified under Regulatory Filings (RNS) as it does not fit the other categories such as Annual Report, Earnings Release, or Capital/Financing Update. The document length (15,000 characters) and content confirm it is a substantive regulatory filing related to IPO sponsorship and listing approval.
2021-01-20 Chinese
关于公司设立以来股本演变情况的说明及其董监高的确认意见
Share Issue/Capital Change Classification · 95% confidence The document is a detailed explanation of the company's share capital evolution and changes in shareholding since its establishment. It includes extensive tables and descriptions of share transfers, capital increases, and changes in shareholder structure over many years. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a brief announcement or a presentation. The content focuses on share capital changes and shareholder confirmations, which aligns with disclosures related to major shareholding notifications or capital changes. However, since it covers the history and evolution of share capital and shareholder structure comprehensively, it is best classified under Share Issue/Capital Change (SHA). The document length and detail confirm it is the report itself, not just an announcement of a report.
2021-01-20 Chinese
公司第六届董事会第六次会议决议
Regulatory Filings
2021-01-20 Chinese
首次公开发行股票并在创业板上市提示公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 福建创识科技股份有限公司 on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes information about the issuance process, subscription dates, pricing, investor qualifications, allotment, and regulatory approvals. The content focuses on the IPO issuance details, subscription procedures, and related regulatory compliance, rather than financial results, management changes, or meeting materials. This type of document is best classified as a Capital/Financing Update (CAP) because it provides comprehensive information about the company's capital raising activity through the public issuance of shares.
2021-01-20 Chinese
北京市康达律师事务所关于公司首次公开发行股票并在创业板上市的补充法律意见书（六）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter (补充法律意见书) issued by a law firm (北京市康达律师事务所) regarding the initial public offering (IPO) and listing of 福建创识科技股份有限公司 on the ChiNext board (创业板). It discusses legal compliance, contract terms, revenue recognition policies, and competitive pressures related to the IPO process. The document references multiple prior legal opinions and regulatory feedback from the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange, indicating it is part of the IPO registration and approval process. It is not a financial report, earnings release, or management discussion, but a legal opinion supplementing the IPO application. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance document related to the IPO process, not a standalone audit report or annual report. The document length is substantial and contains detailed legal analysis, not just an announcement or certification, so it is not RPA or a certification filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-01-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.